Everand Logo

Welcome to Everand!

  • STAT

    At a big cardiology meeting, glitzy tech will collide with sober science

    It’s rare that we get actual hard data on whether a new technology we are inviting into our lives is a good idea. But we're about to get some.
    by Matthew Herper Mar 14, 2019 3 minutes
    Jeff Williams, Apple's chief operating officer, speaks about the Apple Watch, at the product launch in September.

    We carry Star-Trek-style pocket computers, and worry that “screen time” is rotting our children’s brains. We know we’re living in the future. But it’s rare that we get actual hard data on whether a new technology we are inviting into our lives is a good idea.

    Such an opportunity will come Saturday, when we’ll learn more about the and its ability to detect serious heart conditions such as atrial fibrillation. Researchers from Stanford will present the results of

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
    When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
    STAT1 min read
    STAT+: Element Biosciences, An Illumina Rival, On Its Genomics Ambitions — And Why It Hasn’t Gone Public
    Element Biosciences' modest growth comes at a time when some other players are struggling in a sequencer market dominated by Illumina.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
    A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

    Related